Gut microbiota and gut-derived metabolites in defining multiple sclerosis phenotypic continuum

• by Federico Montini, Ashutosh Mangalam, Burcu Zeydan, Joseph Murray, Orhun H. Kantarci

• July 1, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

• by Kathryn Wighton

• June 15, 2026

• 3 min

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

• by Kathryn Wighton

• July 7, 2026

• 6 min

Cholinergic regulation of neuroinflammation: linking microglia, immunometabolism, and neuromodulation

• by Hui Guo, Ziyu Yang, Long Cheng

• June 19, 2026